Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

London University Spin-out Company raises funding to develop Innovative Software for Clincial Trials

27.07.2006
IXICO Ltd, a London University spin-out company that has developed innovative software to automate the analysis of digital clinical images used in drug discovery and development, has raised £930,000. The Capital Fund, a £50 million venture capital fund that invests in fast-growth companies in Greater London, provided £100,000, investing alongside high net worth investors who furnished £830,000. The deal marks The Capital Fund’s 40th investment since it was launched in 2002 and IXICO’s management team plans to use the new capital to fund its development programme and significantly grow the business.
Founded in 2004, IXICO provides state of the art image analysis solutions for
pre-clinical and clinical trials that are based on sophisticated computer algorithms devised by its four scientific founders. The company’s software can automatically analyse thousands of digital images, such as MRI, CT and PET scans collected during clinical trials, to provide pharmaceutical companies with fast, accurate results about the impact of potential new drug molecules on disease effects such as brain volume changes in dementia or bone degeneration in arthritis.

Professor Derek Hill, Chief Executive Officer of IXICO Ltd, said: “The current approaches to medical image analysis in clinical trials rely on highly-skilled radiologists and technicians ‘reading’ and painstakingly comparing images that are often acquired at different centres and different points in time. This process is expensive, time consuming and subject to error.

Our service is completely automated and uses sensitive and reproducible algorithms to quantify changes in the patient over time and hence assess the effectiveness or ineffectiveness of a treatment during trials. It can also compensate for the misplacement or movement of a patient in the scanner, compare images taken at different points in time and provide a full audit trial of the analysis process. As our service is scaleable, it can be used to analyse thousands of images in very early drug tests or in late phase trials. The end result for patients is the faster development of new, more effective treatments for painful or life threatening conditions.”

IXICO’s service has been shown to be effective in a wide variety of medical applications though the company’s initial focus is on developing its services to assess the impact of new drugs for rheumatoid arthritis, dementia and oncology. Clients include a number of major pharmaceutical and healthcare companies, for whom IXICO designs bespoke services, and the company is in advanced negotiations with additional prospective customers.

Professor Hill said: “A key feature of our technology is that the image analysis workflows in the programmes can be easily reconfigured to suit the specific requirements of different pharmaceutical companies. And we have designed our technology platform so that their staff can access the analysis results from computers in a variety of locations via a secure web portal.”

This is IXICO’s first institutional fundraising round and follows its recent success in securing a prestigious £140,000 DTI Grant for Research & Development through the London Development Agency.

Professor Hill commented on the fundraising process: “We are delighted with the success of this funding round. We spoke to several funds but were happy to work with The Capital Fund as they were prepared to share the risk with us and our angel investors by providing vital capital on straightforward terms. They have also helped us to introduce key disciplines that will be particularly useful as we grow the business.”

The Capital Fund’s Investment Manager, Helen Reynolds, said: “IXICO has created a truly innovative technology that has the potential for use across a wide range of medical applications. We were impressed by the quality of the research behind the company’s service and the calibre of the management team, especially Derek Hill, who combine substantial experience of the healthcare industry with significant image analysis acquisition know-how. We wish Derek Hill and his team every success with their future plans.”

Margaret Henry | alfa
Further information:
http://www.oxin.co.uk
http://www.thecapitalfund.co.uk

More articles from Information Technology:

nachricht Cloud technology: Dynamic certificates make cloud service providers more secure
15.01.2018 | Technische Universität München

nachricht New discovery could improve brain-like memory and computing
10.01.2018 | University of Minnesota

All articles from Information Technology >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>